Circulating microRNAs: Potential biomarkers for common malignancies

Biomarkers in Medicine

Volumn 9, Issue 2, 2015, Pages 131-151

  Khoury, Samantha ^a   Tran, Nham ^a,b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cancer; Circulating microRNA; Diagnostic biomarkers; Prognostic biomarkers

Indexed keywords

MICRORNA; MICRORNA 10B; MICRORNA 125A; MICRORNA 134; MICRORNA 137; MICRORNA 145; MICRORNA 146A; MICRORNA 146B; MICRORNA 155; MICRORNA 17; MICRORNA 194; MICRORNA 195; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 23A; MICRORNA 302B; MICRORNA 326; MICRORNA 335; MICRORNA 361; MICRORNA 372; MICRORNA 381; MICRORNA 425; MICRORNA 485; MICRORNA 487B; MICRORNA 92; SMALL UNTRANSLATED RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

BODY FLUID; BREAST CANCER; CANCER PROGNOSIS; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC VALUE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; NON SMALL CELL LUNG CANCER; NUCLEOTIDE SEQUENCE; OCCULT BLOOD TEST; PREDICTION; PROSTATE CANCER; REVIEW; SIGMOIDOSCOPY; SMALL CELL LUNG CANCER; STOMACH CANCER; BLOOD; GENETICS; NEOPLASMS; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

MAMMALIA;

BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84923509830     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/BMM.14.102     Document Type: Review

References (161)

1. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 294(5543), 853-858 (2001).
2. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundantxclass of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294(5543), 858-862 (2001).
3. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 294(5543), 862-864 (2001).
4. Tran N, Hutvagner G. Biogenesis and the regulation of the maturation of miRNAs. Essays Biochem. 54(1), 17-28 (2013).
5. Chim SS, Shing TK, Hung EC et al. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 54(3), 482-490 (2008).
6. Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141(5), 672-675 (2008).
7. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
8. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
9. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009).
10. Patnaik SK, Mallick R, Yendamuri S. Detection of microRNAs in dried serum blots. Anal. Biochem. 407(1), 147-149 (2010).
11. Zernecke A, Bidzhekov K, Noels H et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12- dependent vascular protection. Sci. Signal. 2(100), ra81 (2009).
12. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007).
13. Arroyo JD, Chevillet JR, Kroh EM et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108(12), 5003-5008 (2011).
14. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13(4), 423-433 (2011).
15. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim. Biophys. Acta 1775(1), 181-232 (2007).
16. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 16(4), 415-421 (2004).
17. Hunter MP, Ismail N, Zhang X et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3(11), e3694 (2008).
18. Skog J, Wurdinger T, Van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10(12), 1470-1476 (2008).
19. Ismail N, Wang Y, Dakhlallah D et al. Macrophage microvesicles induce macrophage differentiation and miR- 223 transfer. Blood 121(6), 984-995 (2013).
20. Van Balkom BW, De Jong OG, Smits M et al. Endothelial cells require miR-214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood 121(19), 3997-4006, S3991-S3915 (2013).
21. Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2, 282 (2011).
22. Xu L, Yang BF, Ai J. MicroRNA transport: a new way in cell communication. J. Cell Physiol. 228(8), 1713-1719 (2013).
23. Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 38(20), 7248-7259 (2010).
24. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
25. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
26. Hutvagner G, Zamore PD. RNAi: nature abhors a double-strand. Curr. Opin. Genet. Dev. 12(2), 225-232 (2002).
27. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
28. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704-714 (2009).
29. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6(4), 259-269 (2006).
30. Pelosi A, Careccia S, Lulli V et al. miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene 32(31), 3648-3654 (2013).
31. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39(5), 673-677 (2007).
32. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs - the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9(4), 293-302 (2009).
33. Zhang L, Pickard K, Jenei V et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 73(21), 6435-6447 (2013).
34. Feng DD, Zhang H, Zhang P et al. Down-regulated miR- 331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J. Cell Mol. Med. 15(10), 2164-2175 (2010).
35. Liang Z, Wu H, Xia J et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 79(6), 817-824 (2009).
36. Fabbri M, Paone A, Calore F et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl Acad. Sci. USA 109(31), E2110-E2116 (2012).
37. Fabbri M, Paone A, Calore F, Galli R, Croce CM. A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol. 10(2), 169-174 (2013).
38. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18(3), 350-359 (2008).
39. Kamangar F, DoRes. GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
40. He J. Screening for colorectal cancer. Adv. Surg. 45, 31-44 (2011).
41. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348(9040), 1472-1477 (1996).
42. Kronborg O, Fenger C, Olsen J, JØrgensen OD, SØndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 348(9040), 1467-1471 (1996).
43. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br. J. Surg. 95(8), 1029-1036 (2008).
44. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J. Natl Cancer Inst. 91(5), 434-437 (1999).
45. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375(9726), 1624-1633
46. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N. Engl. J. Med. 366(25), 2345-2357 (2012).
47. Segnan N, Armaroli P, Bonelli L et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial - SCORE. J. Natl Cancer Inst. 103(17), 1310-1322 (2011).
48. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10), 1375-1381 (2009).
49. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127(1), 118-126 (2009).
50. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6(3), e17745 (2011).
51. Giráldez MD, Lozano JJ, Ramírez G et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin. Gastroenterol. Hepatol. 11(6), 681-688.e683 (2013).
52. Anna Brunet Vega CP, Irene M, Anna F et al. Eugeni Saigí MicroRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep. 30(1), 320-326 (2013).
53. Luo X, Stock C, Burwinkel B, Brenner H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE 8(5), e62880 (2013).
54. Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR- 338-5p for early detection of colorectal cancer. BMC Cancer 13(1), 280 (2013).
55. Toiyama Y, Takahashi M, Hur K et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J. Natl Cancer Inst. 105(12), 849-859 (2013).
56. Liu G-H, Zhou Z-G, Chen R et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor Biol. 34(4), 2175-2181 (2013).
57. Kobayashi H, Mochizuki H, Sugihara K et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery 141(1), 67-75 (2007).
58. Menéndez P, Padilla D, Villarejo P et al. Prognostic implications of serum microRNA-21 in colorectal cancer. J. Surg. Oncol. 108(6), 369-373 (2013).
59. Shivapurkar N, Weiner LM, Marshall JL et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS ONE 9(1), e84686 (2014).
60. Zanutto S, Pizzamiglio S, Ghilotti M et al. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. Br J. Cancer 110(4), 1001-1007 (2014).
61. Kuo T-Y, Hsi E, Yang IP, Tsai P-C, Wang J-Y, Juo S-HH. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS ONE 7(2), e31587 (2012).
62. Matsuo M, Nakada C, Tsukamoto Y et al. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. Mol. Cancer 12, 15 (2013).
63. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 251(3), 499-505 (2010).
64. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15(7), 673-682 (2010).
65. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12(6), R90 (2010).
66. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119(3), 586-593 (2010).
67. Appaiah H, Goswami C, Mina L et al. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 13(5), R86 (2011).
68. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DSB. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57(1), 84-91 (2011).
69. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 597145 (2011).
70. Van Schooneveld E, Wouters M, Van Der Auwera I et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 14(1), R34 (2012).
71. Schwarzenbach H, Milde-Langosch K, Steinbach B, Müller V, Pantel K. Diagnostic potential of PTEN-targeting miR- 214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 134(3), 933-941 (2012).
72. Sieuwerts A, Mostert B, Bolt-De Vries J et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res. 17, 3600-3618 (2011).
73. Schrauder MG, Strick R, Schulz-Wendtland R et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS ONE 7(1), e29770 (2012).
74. Hu Z, Dong J, Wang L-E et al. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33(4), 828-834 (2012).
75. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta 413(13-14), 1058-1065 (2012).
76. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5(10), e13735 (2010).
77. Cookson V, Bentley M, Hogan B et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell. Oncol. 35(4), 301-308 (2012).
78. Ryu S, Joshi N, McDonnell K et al. Discovery of novel human breast cancer microRNAs from deep sequencing data by analysis of pri-microRNA secondary structures. PLoS ONE 6(2), e16403 (2011).
79. Volinia S, Galasso M, Sana ME et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl Acad. Sci. USA 109(8), 3024-3029 (2012).
80. Farazi TA, Horlings HM, Ten Hoeve JJ et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 71(13), 4443-4453 (2011).
81. Jiang S, Zhang H-W, Lu M-H et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70(8), 3119-3127 (2010).
82. Sun Y, Wang M, Lin G et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE 7(10), e47003 (2012).
83. Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin. J. Cancer Res. 25(1), 46-54 (2012).
84. Wang Py GH, Li Bf, Lv Cl et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol. Lett. 6(6), 1681-1686 (2013).
85. Kim G, Yong Y, Kang HJ et al. Zwitterionic polymer-coated immunobeads for blood-based cancer diagnostics. Biomaterials 35(1), 294-303 (2014).
86. Ng EKO, Li R, Shin VY et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS ONE 8(1), e53141 (2013).
87. Mar-Aguilar F, Mendoza-Ramirez JA, Malagón-Santiago I et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis. Markers 34(3), 163-169 (2013).
88. Chan M, Liaw CS, Ji SM et al. Identification of circulating microRNA signatures for breast cancer detection. Clin. Cancer Res. 19(16), 4477-4487 (2013).
89. Cuk K, Zucknick M, Heil J et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer 132(7), 1602-1612 (2013).
90. Cuk K, Zucknick M, Madhavan D et al. Plasma microRNA panel for minimally invasive detection of breast cancer. PLoS ONE 8(10), e76729 (2013).
91. Zeng R-C, Zhang W, Yan X-Q et al. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med. Oncol. 30(1), 1-8 (2013).
92. Chen W, Cai F, Zhang B, Barekati Z, Zhong X. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumor Biol. 34(1), 455-462 (2013).
93. Si H, Sun X, Chen Y et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 139(2), 223-229 (2013).
94. Madhavan D, Zucknick M, Wallwiener M et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18(21), 5972-5982 (2012).
95. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 59(10), 1489-1496 (2013).
96. Haythorn MR, Ablin RJ. Prostate-specific antigen testing across the spectrum of prostate cancer. Biomark. Med. 5(4), 515-526 (2011).
97. Canto EI, Slawin KM. Early management of prostate cancer. How to respond to an elevated PSA? Annu. Rev. Med. 53(1), 355-368 (2002).
98. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies model estimates of potential benefits and harms. Ann. Intern. Med. 158(3), 145-153 (2013).
99. Moltzahn F, Olshen AB, Baehner L et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71(2), 550-560 (2011).
100. Yaman Agaoglu F, Kovancilar M, Dizdar Y et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 32(3), 583-588 (2011).
101. Mahn R, Heukamp LC, Rogenhofer S, Von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265.e1269-1265.e1216 (2011).
102. Bryant RJ, Pawlowski T, Catto JWF et al. Changes in circulating microRNA levels associated with prostate cancer. Br J. Cancer 106(4), 768-774 (2012).
103. Chen Z-H, Zhang G-L, Li H-R et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate 72(13), 1443-1452 (2012).
104. Selth LA, Townley SL, Bert AG et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J. Cancer 109(3), 641-650 (2013).
105. Shen J, Hruby GW, McKiernan JM et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72(13), 1469-1477 (2012).
106. Nguyen HCN, Xie W, Yang M et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73(4), 346-354 (2013).
107. Watahiki A, MacFarlane R, Gleave M et al. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int. J. Mol. Sci. 14(4), 7757-7770 (2013).
108. Cheng HH, Mitchell PS, Kroh EM et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS ONE 8(7), e69239 (2013).
109. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS ONE 4(7), e6229 (2009).
110. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA. Cancer J. Clin. 59(4), 225-249 (2009).
111. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28(10), 1721-1726 (2010).
112. Yu S-L, Chen H-Y, Chang G-C et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1), 48-57 (2008).
113. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 6(3), 482-488 (2011).
114. Chen Q, Si Q, Xiao S et al. Prognostic significance of serum miR-17-5p in lung cancer. Med. Oncol. 30(1), 1-6 (2012).
115. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J. Cancer Res. Clin. Oncol. 138(12), 2045-2050 (2012).
116. Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer (Amsterdam, The Netherlands) 81(3), 388-396 (2013).
117. Yu H, Jiang L, Sun C et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene 534(1), 60-65 (2014).
118. Zhang W-H, Gui J-H, Wang C-Z et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol. Res. 20(4), 139-147 (2012).
119. Zheng D HS, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX.. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4(6), 575-586 (2011).
120. Heegaard NHH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int. J. Cancer 130(6), 1378-1386 (2012).
121. Kaduthanam S, Gade S, Meister M et al. Serum miR- 142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer (Amsterdam, The Netherlands) 80(2), 223-227 (2013).
122. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L. Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol. Ther. 14(12), 1104-1112 (2013).
123. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PLoS ONE 7(9), e46045 (2012).
124. Tomasetti M, Staffolani S, Nocchi L et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin. Biochem. 45(7-8), 575-581 (2012).
125. Akbas F, Coskunpinar E, Aynaci E, Müsteri Oltulu Y, Yildiz P. Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Exp. Lung Res. 38(6), 286-294 (2012).
126. Han H-S, Yun J, Lim S-N et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int. J. Cancer 133(3), 645-652 (2013).
127. Abd-El-Fattah A, Sadik N, Shaker O, Aboulftouh M. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochem. Biophys. 67(3), 875-884 (2013).
128. Aushev VN, Zborovskaya IB, Laktionov KK et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS ONE 8(10), e78649 (2013).
129. Le H-B, Zhu W-Y, Chen D-D et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med. Oncol. 29(5), 3190-3197 (2012).
130. Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR-361-3p and miR-625∗as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7(6), e38248 (2012).
131. Pan Z, Pang L, Ding B et al. Gastric cancer staging with dual energy spectral CT imaging. PLoS ONE 8(2), e53651 (2013).
132. Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin. Radiol. 68(3), 251-255 (2013).
133. Gong J, Kang W, Zhu J, Xu J. CT and MR imaging of gastrointestinal stromal tumor of stomach: a pictorial review. Quant. Imaging Med. Surg. 2(4), 274-279 (2012).
134. Liu R, Zhang C, Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47(5), 784-791 (2010).
135. Okubo M, Tahara T, Shibata T et al. Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter 15(6), 524-531 (2010).
136. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 102(7), 1174-1179 (2010).
137. Zhou H, Guo J-M, Lou Y-R et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. 88(7), 709-717 (2010).
138. Zheng Y, Cui L, Sun W et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 10(2), 71-77 (2011).
139. Komatsu S, Ichikawa D, Tsujiura M et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33(1), 271-276 (2013).
140. Kim SY, Jeon TY, Choi CI et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J. Mol. Diagn. 15(5), 661-669 (2013).
141. Chen Q, Ge X, Zhang Y et al. Plasma miR-122 and miR- 192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncol. Rep. 31(4), 1863-1870 (2014).
142. Tsai Kw LY, Wu Cw, Hu Ly et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 51(4), 394-401 (2012).
143. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med. 10(1), 186 (2012).
144. Li C, Li JF, Cai Q et al. MiRNA-199a-3p: a potential circulating diagnostic biomarker for early gastric cancer. J. Surg. Oncol. 108(2), 89-92 (2013).
145. Tsujiura M, Komatsu S, Ichikawa D et al. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer doi:10.1007/s10120-014-0363-1 (2014) (Epub ahead of print).
146. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 138(10), 1659-1666 (2012).
147. Liu R, Zhang C, Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47(5), 784-791 (2011).
148. Gorur A, Balci Fidanci S, Dogruer Unal N et al. Determination of plasma microRNA for early detection of gastric cancer. Mol. Biol. Rep. 40(3), 2091-2096 (2013).
149. Wang J, Chen J, Chang P et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila Pa) 2(9), 807-813 (2009).
150. Wang X, Tang S, Le SY et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3(7), e2557 (2008).
151. Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol. Rev. 253(1), 167-184 (2013).
152. Staedel C, Darfeuille F. MicroRNAs and bacterial infection. Cell. Microbiol. 15(9), 1496-1507 (2013).
153. Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS ONE 9(2), e89565 (2014).
154. Prochazka M, Granath F, Ekbom A, Shields PG, Hall P. Lung cancer risks in women with previous breast cancer. Eur J. Cancer 38(11), 1520-1525 (2002).
155. Kirschner MB, Kao SC, Edelman JJ et al. Haemolysis during sample preparation alters microRNA content of plasma. PLoS ONE 6(9), e24145 (2011).
156. Pritchard CC, Kroh E, Wood B et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res. (Phila) 5(3), 492-497 (2012).
157. Sawant RB, Jathar SK, Rajadhyaksha SB, Kadam PT. Red cell hemolysis during processing and storage. Asian J. Transfus. Sci. 1(2), 47-51 (2007).
158. Noe DA, Weedn V, Bell WR. Direct spectrophotometry of serum hemoglobin: an Allen correction compared with a three-wavelength polychromatic analysis. Clin. Chem. 30(5), 627-630 (1984).
159. Kirschner MB, Van Zandwijk N, Reid G. Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front. Genet. 4, 56 (2013).
160. Weber JA, Baxter DH, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-1741 (2010).
161. Park NJ, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15(17), 5473-5477 (2009).